Description
Ruxolitinib, marketed under the brand name JAKAFI, It is an prescription medication that has been approved by the FDA for several conditions at different dates:
Approved on May 24, 2019 for adult and pediatric patients 12 years and older
Chronic graft-versus-host disease (cGVHD)
Approved on September 22, 2021 for adult and pediatric patients 12 years and older
Polycythemia vera
Approved on December 4, 2014, the first FDA-approved drug for this condition
Atopic dermatitis (AD)
Approved in September 2021 as a cream under the brand name Opzelura for mild to moderate AD
Vitiligo
Approved in July 2022 as a cream under the brand name Opzelura.
What is JAKAVI (ruxolitinib) ?
Jakafi is a kinase inhibitor indicated for treatment of:
- intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.
- polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.
- steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.
How to order approved “JAKAVI (ruxolitinib) for Tablets” Medicine?
JAKAFI (Ruxolitinib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing JAKAFI and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
We can ship to :
Verve Biosciences offers assistance in importing the anti-cancer medication JAKAVI (ruxolitinib) for Tablets. To inquire about the total cost of JAKAVI (ruxolitinib) for Tablets in various countries, including UAE, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, as well as Europe (such as UK, Hungary, Ireland, Latvia, Slovakia, Czech Republic, Belgium, Lithania, Greece, Spain, Maldova, Germany, Sweden, Italy, Bulgaria, Romania, Montenegro, Russia), and other countries like Zimbabwe, Australia, and New Zealand, Canada, Philippines, USA, South Africa, Thailand, China, Pakistan, Kazakhstan, Uzbekistan, Zambia, Kuwait, Sri Lanka, Singapore, Hong Kong, Afghanistan, Turkey, Malaysia, Qatar, Japan, Nepal, and many other countries. please reach out to us. We will provide you with the necessary information regarding the pricing and availability of JAKAVI (ruxolitinib) for Tablets in the desired locations.
How to Get Access
If the Brand Name medication “JAKAVI (ruxolitinib) for Tablets” is not approved or unavailable in your country, patients, physicians, and distributors/suppliers have the option to purchase and import it from Verve Biosciences. To begin the process, you can make an enquiry, and we will assist you in calculating the total cost to buy “JAKAVI (ruxolitinib) for Tablets” online and arrange delivery to your location. To proceed, we will require a prescription from your treating doctor, and in certain countries, an import license may also be necessary. Throughout the process, our Patient Support team will provide guidance and support.
Verve Biosciences Pvt. Ltd.
Contact Person : Mr Rakesh Khanna
Email: info@cancermedicinesnetwork.com
Mobile: 91 9910645395
WhatsApp: +919910645395
FAQ's
How much does JAKAVI cost?
The JAKAVI price in India usually can vary depending on the wholesaler/pharmacy you visit. JAKAVI is available as a brand name drug only, a generic version is not yet available.
What is the best price for ruxolitinib?
Please contact at urgent@cancermedicinesnetwork.com : (+91) 9910645395 for ruxolitinib price India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Can I get JAKAVI (ruxolitinib) for Tablets even if I am not based in India?
The Verve Biosciences helps patients in accessing or importing JAKAVI (ruxolitinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.
